Global Human Immunodeficiency Virus (HIV) Therapeutics Industry to 2029 - Drug Forecast and Market Analysis - ResearchAndMarkets.com

The "Human Immunodeficiency Virus (HIV) Therapeutics - Global Drug Forecast and Market Analysis to 2029" report has been added to ResearchAndMarkets.com's offering.

The publisher projects the global HIV marketplace will experience modest growth during the forecast period. The HIV therapeutics market was valued at $22.9B in 2019. The launch of long-acting injectable therapies and continued success of single-tablet regimens (STRs) will drive growth in the market, which will expand at a Compound Annual Growth Rate (CAGR) of 2%. By 2029, sales of anti-HIV therapeutics will reach $28B.

Over three decades ago, researchers identified the human immunodeficiency virus (HIV) as the causative agent of a then-mysterious new illness, Acquired Immunodeficiency Syndrome (AIDS). A member of the Lentivirus genus, HIV belongs to the family of retroviruses, which are RNA viruses with the ability to reverse transcribe their single-stranded RNA genome into double-stranded DNA. Following reverse transcription, the viral DNA is incorporated into the host cell genome. An estimated 75 million people have been infected with HIV since 1981, and AIDS has claimed the lives of more than 32 million people. In some countries, AIDS is the leading cause of death. Globally, one million people die from AIDS-related infections per year.

Companies Mentioned

• Abbvie
• Aelix Therapeutics
• BioNTech
• Biosantech
• BMS
• Boehringer Ingelheim
• CytoDyn
• Dewpoint Therapeutics
• Gilead Sciences
• GlaxoSmithKline
• Starpharma
• ImmunityBio
• Janssen
• Japan Tobacco
• Johnson and Johnson
• Merck
• Mylan
• Roche
• Shionogi
• TaiMed Biologics
• Theratechnologies
• ViiV Healthcare
• AIM ImmunoTech

Key Highlights

• The global HIV market was worth an estimated $22.9B in 2019. The publisher projects that this market will expand at a Compound Annual Growth Rate (CAGR) of 2%, reaching $28B in 2029.
• Growth in the market is expected to be facilitated by the entry of non-oral therapies and pre-exposure prophylactic (PrEP) drugs, which will launch in all of the 7MM by the end of the forecast period.
• The long-term efficacy of the pharmacologic management of HIV is highly dependent on patient compliance. Poor compliance is a risk factor for a shortened life expectancy and greater chance of contracting opportunistic infections. Pharmaceutical companies are attempting to address this issue by developing injectable therapies that are administered less frequently than market-leading oral drugs which are taken daily and are linked to side effects such as osteoporosis, hepatotoxicity, and kidney dysfunction.
• By 2029, the US and 5EU markets will benefit from an influx of therapeutic agents that address different stages of HIV infection, including viral entry, reverse transcription, and integration of viral DNA into the host genome.
• There will be several drivers that promote growth in the HIV therapeutics market. One example is the fact that non-oral therapies will launch in the 7MM. These drugs will diversify treatment options for patients. Other market drivers include the use of drugs with low frequencies of administration and the emergence of biologic drugs that have high annual costs of therapy (ACOT) which can be used to treat patients with multidrug-resistant infections.
• Major barriers to growth in the HIV market during the forecast period will include the fact that social stigma prevents patients from seeking a diagnosis leading to a low diagnosis rate, increased disease transmission, and delayed initiation of antiretroviral therapy (ART). The publisher also expects that lack of compliance among patients will persist, either because of the need to take multiple oral tablets on a daily basis in some treatment regimens, or because of undesirable side effects such as weight gain, changes in bone mineral density, lactic acidosis, or mental disorders.

Key Questions Answered in This Report

• What were the market leading drugs for HIV in 2019?
• When will the late-stage pipeline products launch in each of the 7MM?
• What are the major clinical and environmental unmet needs in the HIV market?
• What are the key commercial opportunities for pharmaceutical companies developing therapies for HIV?
• What effect has COVID-19 had on the development and administration of HIV therapeutics?

Key Topics Covered:

1 Table of Contents

2 Human Immunodeficiency Virus: Executive Summary

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Overview

4.1.2 Etiology

4.1.3 Pathophysiology

4.2 Clinical Stages of HIV Infection

4.3 Prognosis and Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.5 Epidemiological Forecast for HIV (2019-2029)

5.6 Discussion

6 Disease Management

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Introducing Non-Oral Therapies to Diversify Treatment Options for Patients

8.3 Therapies with Improved Safety and Tolerability Profiles

8.4 Improved Diagnosis Rates and Access to PrEP

8.5 Clearer Treatment Guidelines for General Practitioners and Primary Care Providers

9 Pipeline Assessment

9.1 Overview

9.2 Clinical Trials

9.3 Late-Stage Pipeline Agents

9.4 Innovative Drugs in Clinical Development

9.5 Vaccines

10 Current and Future Players

11 Market Outlook

11.1 Global Markets

11.2 US

11.3 5EU

11.4 Japan

12 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/8i8xfb

View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005493/en/